PYSZCZYMUKA GREG 4
4 · AYTU BIOPHARMA, INC · Filed Jan 2, 2024
Insider Transaction Report
Form 4
PYSZCZYMUKA GREG
Chief Commercial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-12-31−209→ 1,042 total→ Common Shares (209 underlying) - Exercise/Conversion
Common Shares
2023-12-31+209→ 22,560 total
Footnotes (1)
- [F1]Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.